SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Brown RS, Rush SH, Rosen HR. Liver and intestine transplantation. OPTN/SRTR 2003 Annual Report. (City of Publication: Publisher not available), 2003.
  • 2
    Bismuth H, Figueiro J, Samuel D. What should we expect from a bioartificial liver in fulminant hepatic failure? Artif. Organs 1998; 22: 2631.
  • 3
    Lee C, Tink A. Exchange transfusion in hepatic coma: Report of a case. Med. J. Aust. 1958; 1: 402.
  • 4
    Trey C, Burns DG, Saunders SJ. Treatment of hepatic coma by exchange blood transfusion. N. Engl. J. Med. 1966; 274: 47381.
  • 5
    Ritt DJ, Whelan G, Werner DJ, Eigenbrodt EH, Schenker S, Combes B. Acute hepatic coma necrosis with stupor or coma. An analysis of 31 patients. Medicine 1969; 48: 15172.
  • 6
    McKechnie JC, Hersh T. Exchange transfusion in hepatic coma. A review of 19 cases. Am. J. Gastroenterol. 1971; 56: 1743.
  • 7
    Redeker AG, Yamahiro H. Controlled trial of exchange transfusion therapy in fulminant hepatitis. Lancet 1973; 1: 36.
  • 8
    Sabin S, Merritt JA. Treatment of hepatic coma in cirrhosis by plasmapheresis and plasma infusion (plasma exchange). Ann. Intern. Med. 1968; 68: 17.
  • 9
    Inoue N. Continuous flow membrane plasmapheresis utilizing cellulose acetate hollow fibre in acute hepatic failure. In: BrunnerG, ScmidtFW, eds. Artificial Liver Support. London: Springer-Verlag, 1981; 12631.
  • 10
    Kondrup J, Almdal T, Vilstrup H, Tygstruo N. High volume plasma exchange in fulminant hepatic failure. Int. J. Artif. Organs 1992; 15: 66976.
  • 11
    Larsen FS, Hansen BA, Jorgensen LG, Secher NH, Kirkegaard P, Tygstrup N. High volume plasmapheresis and acute liver transplantation in fulminant hepatic failure. Transplant. Proc. 1994; 26: P1789.
  • 12
    Merrill JH, Smith SI, Calahan EJI. The use of an artificial kidney: II Clinical experience. J. Clin. Invest. 1950; 29: 45238.
  • 13
    Kiley JE, Pender JC, Welch HF. Ammonia intoxication treated by haemodialysis. N. Engl. J. Med. 1958; 259: 115661.
  • 14
    Opolon P, Rapin JR, Huguet C et al. Hepatic failure coma (HFC) treated by polyacylonitrile membrane (PAN) haemodialysis (HD). Trans. Am. Soc. Artif. Intern. Organs 1976; 22: 70110.
  • 15
    Opolon P. Large pore hamodialysis in fulminant hepatic failure. In: BrunnerG, SchmidtFW, eds. Artificial Liver Support. London: Springer-Verlag, 1981; 12631.
  • 16
    Silk DB, Williams R. Experiences in the treatment of fulminant hepatic failure by conservative therapy, charcoal haemoperfusion and polyacrylonitrile haemodialysis. Int. J. Artif. Organs 1978; 1: 2933.
  • 17
    Denis J, Opolon P, Delmore ML. Longterm extracorporeal assistance by continuous haemofiltration during fulminant hepatic failure. Gastroenterol. Clin. Biol. 1979; 3: 33748.
  • 18
    Rakela J, Kurtz SB, McCarthy JT et al. Postdilution hemofiltration in the management of acute hepatic failure: A pilot study. Mayo Clin. Proc. 1988; 63: 11318.
  • 19
    Matsubara S, Okabe K, Ouchi K et al. Continuous removal of middle molecules by hemofiltration in a patient with acute liver failure. Crit. Care Med. 1990; 18: 13318.
  • 20
    Gimson AE, Braude S, Mellon PJ, Canalese J, Williams R. Earlier charcoal haemoperfusion in fulminant hepatic failure. Lancet 1982; 2: 6813.
  • 21
    O'Grady JG, Gimson AE, O'Brien CJ, Pucknell A, Hughes RD, Williams R. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988; 94 (5 Part 1): 118692.
  • 22
    Bihari D, Hughes RD, Gimson AE et al. Effects of serial resin hemoperfusion in fulminant hepatic failure. Int. J. Artif. Organs 1983; 6: 299302.
  • 23
    Hughes RD, Pucknell A, Routley D, Langley PG, Wendon JA, Williams R. Evaluation of the BioLogic-DT sorbent-suspension dialyser in patients with fulminant hepatic failure. Int. J. Artif. Organs 1994; 17: 65762.
  • 24
    Kimoto S. The artificial liver experiments and clinical applications. ASAIO Trans. 1959; 5: 10210.
  • 25
    Hori M, Neto AC, Austen WC, McDermott WVJ. Isolated in vivo hepatorenal perfusion in the dog. Circulatory and functional response of the kidney to hepatic anoxia. J. Surg. Res. 1967; 7: 41317.
  • 26
    Burnell JM, Dawborn JK, Epstein RB et al. Acute hepatic coma treated by cross-circulation or exchange transfusion. N. Engl. J. Med. 1967; 276: 93543.
  • 27
    Nose Y, Mikami J, Kasai Y, Sasaki E, Agishi T, Danjo Y. An experimental artificial liver utilizing extracorporeal metabolism with slices of granulated canine liver. Trans. Am. Soc. Artif. Intern. Organs 1963; 9: 35862.
  • 28
    Working party on xenotransplantation, Council of Europe. Working Report; 2000 July. Report No. CDB1/CDSP-XENO (2000) 12. (City of publication: Publisher not available).
  • 29
    Eiseman B, Liem DS, Raffucci F. Heterologous liver perfusion in treatment of hepatic failure. Ann. Surg. 1965; 162: 32945.
  • 30
    Fox IJ, Langnas AN, Fristoe LW et al. Successful application of extracorporeal liver perfusion: A technology whose time has come. Am. J. Gastroenterol. 1993; 88: 187681.
  • 31
    Chari RS, Collins BH, Magee JC et al. Brief report: Treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation [see comments]. N. Engl. J. Med. 1994; 331: 2347.
  • 32
    Levy MF, Crippin J, Sutton S et al. Liver allotransplantation after extracorporeal hepatic support with transgenic (hCD55/hCD59) porcine livers: Clinical results and lack of pig-to-human transmission of the porcine endogenous retrovirus. Transplantation 2000; 69: 27280.
  • 33
    Habibullah CM, Syed IH, Qamar A, Taher UZ. Human fetal hepatocyte transplantation in patients with fulminant hepatic failure. Transplantation 1994; 58: 9512.
  • 34
    Fox IJ, Roy-Chowdhury J. Hepatocyte transplantation. J. Hepatol. 2004; 40: 87886.
  • 35
    Stange J, Mitzner S, Ramlow W, Gliesche T, Hickstein H, Schmidt R. A new procedure for the removal of protein bound drugs and toxins. ASAIO J. 1993; 39 (Suppl.): M6215.
  • 36
    Falkenhagen D, Strobl W, Vogt G et al. Fractionated plasma separation and adsorption system: A novel system for blood purification to remove albumin bound substances. Artif. Organs 1999; 23: 816.
  • 37
    Rifai K, Ernst T, Kretschmer U et al. Prometheus – a new extracorporeal system for the treatment of liver failure. J. Hepatol. 2003; 39: 98490.
  • 38
    Sauer IM, Gerlach JC. Modular extracorporeal liver support. Artif. Organs 2002; 26: 7036.
  • 39
    Mitzner SR, Stange J, Klammt S, Peszynski P, Schmidt R, Noldge-Schomburg G. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J. Am. Soc. Nephrol. 2001; 12 (Suppl. 17): S7582.
  • 40
    Sen S, Davies NA, Mookerjee RP et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: A randomized controlled study. Liver Transpl. 2004; 10: 110919.
  • 41
    Schmidt LE, Wang LP, Hansen BA, Larsen FS. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: A prospective controlled trial. Liver Transpl. 2003; 9: 2907.
  • 42
    Mitzner SR, Stange J, Klammt S et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS. Results of a prospective, randomized, controlled clinical trial [comment]. Liver Transpl. 2000; 6: 27786.
  • 43
    Heemann U, Treichel U, Loock J et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: A prospective, controlled study [comment]. Hepatology 2002; 36 (4 Part 1): 94958.
  • 44
    Sen S, Jalan R, Williams R. Extracorporeal albumin dialysis in acute-on-chronic liver failure: Will it stand the test of time? [Comment]. Hepatology 2002; 36 (4 Part 1): 101416.
  • 45
    Khuroo MS, Farahat KL. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: A meta-analysis. Liver Transpl. 2004; 10: 1099106.
  • 46
    Stange J. Meta-analysis in albumin dialysis: Are we really ready for it. Liver Transpl. 2004; 10: 11078.
  • 47
    Jalan R, Sen S, Williams R. Prospects for extracorporeal liver support. Gut 2004; 53: 8908.
  • 48
    Ellis AJ, Hughes RD, Wendon JA et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996; 24: 144651.
  • 49
    Kong LB, Chen S, Demetriou AA, Rozga J. Matrix-induced liver cell aggregates (MILCA) for bioartificial liver use. Int. J. Artif. Organs 1996; 19: 728.
  • 50
    Kamohara Y, Rozga J, Demetriou AA. Artificial liver. review and Cedars-Sinai experience. J. Hepatobiliary Pancreat. Surg. 1998; 5: 27385.
  • 51
    Demetriou AA, Brown Jr RS, Busuttil RW et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann. Surg. 2004; 239: 6607.
  • 52
    Watanabe FD, Mullon CJ, Hewitt WR et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann. Surg. 1997; 225: 48491; discussion 491–4.
  • 53
    Chen SC, Hewitt WR, Watanabe FD et al. Clinical experience with a porcine hepatocyte-based liver support system. Int. J. Artif. Organs 1996; 19: 6649.
  • 54
    Busse B, Gerlach J. The Berlin extracorporeal liver support system. In: BerryM, EdwardsA, eds. The Hepatocyte Review. Dordrecht: Kluwer Academic Publishers, 2000; 56174.
  • 55
    Robert A, Chamuleau RA, Flendrig LM. The bioartificial liver of the Academic Medical Centre of Amsterdam. In: BerryM, EdwardsA, eds. The Hepatocyte Review. Dordrecht: Kluwer Academic Publishers, 2000; 57584.
  • 56
    Martin U, Kiessig V, Blusch JH et al. Expression of pig endogenous retrovirus by primary porcine endothelial cells and infection of human cells [comment]. Lancet 1998; 352: 6924.
  • 57
    Wilson CA, Wong S, Muller J, Davidson CE, Rose TM, Burd P. Type C retrovirus released from porcine primary peripheral blood mononuclear cells infects human cells. J. Virol. 1998; 72: 30827.
  • 58
    Nyberg SL, Hibbs JR, Hardin JA, Germer JJ, Persing DH. Transfer of porcine endogenous retrovirus across hollow fiber membranes: Significance to a bioartificial liver [see comments]. Transplantation 1999; 67: 12515.
  • 59
    Martin U, Winkler ME, Id M et al. Productive infection of primary human endothelial cells by pig endogenous retrovirus (PERV). Xenotransplantation 2000; 7: 13842.
  • 60
    Van Der Laan LJ, Lockey C, Griffeth BC et al. Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice [see comment]. Nature 2000; 407: 904.
  • 61
    Nyberg SL, Remmel RP, Mann HJ, Peshwa MV, Hu WS, Cerra FB. Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functions in a bioartificial liver. Ann. Surg. 1994; 220: 5967.
  • 62
    Hoekstra R, Chamuleau RA. Recent developments on human cell lines for the bioartificial liver. Int. J. Artif. Organs 2002; 25: 18291.
  • 63
    Strom S, Fisher R. Hepatocyte transplantation: New possibilities for therapy [comment]. Gastroenterology 2003; 124: 56871.
  • 64
    Yagi T, Hardin JA, Valenzuela YM, Miyoshi H, Gores GJ, Nyberg SL. Caspase inhibition reduces apoptotic death of cryopreserved porcine hepatocytes. Hepatology 2001; 33: 143240.
  • 65
    Catapano G. Mass transfer limitations to the performance of membrane bioartificial liver support devices. Int. J. Artif. Organs 1996; 19: 1835.
  • 66
    Catapano G, De Bartolo L. Importance of the kinetic characterization of liver cell metabolic reactions to the design of hybrid liver support devices. Int. J. Artif. Organs 1996; 19: 6706.
  • 67
    Catapano G. Theoretical and practical considerations on the design of hybrid liver support devices. In: CrepaldiG, DemetriouAA, MuracaM, eds. Bioartificial Liver Support Systems. The Critical Issues. Rome: CIC edizioni internationale, 1997; 1726.